Journal
JOURNAL OF INORGANIC BIOCHEMISTRY
Volume 106, Issue 1, Pages 32-42Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jinorgbio.2011.08.013
Keywords
Gold(III); Au(III); Polypyridyl; Cellular uptake; DNA binding affinity; Anticancer
Ask authors/readers for more resources
Gold(III) compounds have been recognized as anticancer agents due to their structural and electronic similarities with currently employed platinum(II) species. An added benefit to gold(III) agents is the ability to overcome cisplatin resistance. This work identified four gold(III) compounds, [Au(Phen)Cl-2]PF6, [Au(DPQ) Cl-2]PF6, [Au(DPPZ)Cl-2]PF6, and [Au(DPQC)Cl-2]PF6, (Phen = 1,10-phenanthroline, DPQ = dipyrido[3,2d:2',3'-f]quinoxaline. DPPZ = dipyrido[3,2-a:2',3'-c] phenazine, DPQC = dipyrido[3,2-d:2',3'-f] cyclohexyl quinoxaline) that exhibited anticancer activity in both cisplatin sensitive and cisplatin resistant ovarian cancer cells. Two of these compounds, [Au(DPQ)Cl-2]PF6 (AQ) and [Au(DPPZ)Cl-2]PF6 (AZ), displayed exceptional anticancer activity and were the focus of more intensive mechanistic study. At the molecular level, AQand AZ formed DNA adducts, generated free radicals, and upregulated pro-apoptotic signaling molecules (p53, caspases, PARP, death effectors). Taken together, these two novel gold(III) polypyridyl complexes exhibit potent antitumor activity in cisplatin resistant cancer cells. These activities may be mediated, in part, by the activation of apoptotic signaling. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available